CompletedPhase 2NCT00874978

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: King's College Hospital NHS Trust
Principal Investigator: Ghulam J Mufti, MB, DM, FRCP, FRCPath
King's College London
Intervention: lenalidomide(drug)
Enrollment: 36 target
Eligibility: 18 years · All sexes
Timeline: 2005 – 2016

Study locations (1)

King's College Hospital NHS Foundation Trust, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00874978 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality →

← Back to all trials